DAYARAM Pharmaceutical and our group companies DAYARAM are the one of largest manufacturer andsupplier of Granisetron formulations and Granisetron API inAnkleshwar, Gujarat, India. We are sullying the best quality of Granisetron API all around the India as well as in thewhole world. Our product Granisetronpraised byour clients and also by the other companies.
DAYARAM Pharmaceutical exporting very big quantity of the finesquality products of Granisetron inall over world for many years in acountries like Romania, Finland, Malaysia, Netherland, South Africa, Brazil,Egypt, Singapore, Jordan, Lebanon, Israel, Vietnam, Bangladesh, Paraguay,Argentina, Dominican Republic, Sudan, Hong Kong, Seychelles, Algeria, Iran, Uruguay,Russia, Thailand, Afghanistan, Latvia, Lithuania, United Arab Emirates,Seychelles, Peru, Switzerland, Tunisia, France, Hungary, Finland, Turkey,Pakistan, Rwanda, South Africa, Denmark, Malawi, Croatia, Slovenia, Ireland,Zambia, Cyprus, Nigeria, Uzbekistan, Cameroon, Netherlands, Azerbaijan,Venezuela, Morocco, Cote D Ivoire, St Lucia, South Korea, Congo, Philippines,Colombia Sweden, Hungary, Mauritius, Vanuatu, Malta, Kazakistan, Slovenia,Bolivia, Japan, Uganda, Australia and many more countries.
DAYARAM Pharmaceutical also supply large quantity of Granisetron products in Indian stateslike Gujarat, Haryana, Rajasthan, Madhya Pradesh, Kerala, Tamilnadu, Delhi,Bihar, Uttar Pradesh, Assam, Goa, Hyderabad, Telangana, Mizoram, Sikkim etc.
Granisetron belongs to the class of 5-HT3 receptorantagonist. Granisetron prevents nausea and vomiting by serotonin which is anatural substance which can cause nausea and vomiting.
Granisetron used as an antiemetic agent to treatvomiting and nausea in the treatment like chemotherapy. This drug did not haveeffect in motion sickness and it will not effect on dopamine receptors.
SYNONYMS OF GRANISETRON: Granistron, Granisetrn, Granisetron,Granisetronum
IUPAC NAME: 1-Methyl-N-((1R, 3r, 5S)-9-methyl-9-azabicyclononan-3-yl)-1H-indazole-3-carboxamide
CAS NO: 109889-09-0
MOLECULAR FORMULA: C18H24N4O
MOLECULAR MASS: 312.41 g/mol
STORAGE OF GRANISETRON: Keep medication is cool and dry place, donot store in bathroom or kitchen. Keep all medication away from children andpets.
HOW TO USE: Granisetron comes in oral dosage form liketablet; it is consumed by mouth with water. Take the medicine 1hr before thechemotherapy. And take second dose after the 12hr interval of first dose.
HOW GRANISETRON WORKS: Granisetron gives antiemetic activity byinhibiting the 5-HT3 receptor which are located in centrally and peripherallyin the body. By this process the natural serotonin secretion inhibited and bythis the nausea and vomiting is prevented.
PHARMACOKINETICS OF GRANISETRON: The main absorptionof Granisetron is done by the oral and it is rapid and complete. As the resultof first pass metabolism the oral bioavaibility is reduced about 60%. The half-lifeof Granisetron in the cancer patients is 9-12hrs and in the normal patient thehalf-life is 4-6hrs. The 48% excretion of Granisetron is done by urination andremaining will excreted in faces.
SIDE EFFECTS OF GRANISETRON: There are some commonside effects of Granisetron is headache, dizziness, fever, pain, redness andswelling on the injection point. Tell your doctor if you see side effects likestomach/abdominal pain, chest pain, fast irregular heartbeats, hallucination,loss of coordination, muscle pain etc. The allergic reactions by theGranisetron are rare but if you develop symptoms like rash, itching orirritation consult your doctor.
PRECAUTIONS: Tell your doctor if you are allergic toGranisetron or its residues. Before using the Granisetron tell your doctor ifyou have any past related to stomach or intestinal problem like swelling orsurgery. Tell your doctor if you have certain history related to heartproblems. Talk to your doctor about taking Granisetron safely.
CDSCO APPROVAL OF GRANISETRON: Granisetron tabletsare approved by CDSCO in India in 05.07.2000
FORMULATIONS AVAILABLE IN MARKET:
Note: Product protected by valid patents are notoffered for sale in countries where such patents are still valid and itsliability is at Buyers Risk